William Blair started coverage on shares of uniQure (NASDAQ:QURE – Free Report) in a research note published on Wednesday, MarketBeat.com reports. The brokerage issued an outperform rating on the biotechnology company’s stock.
QURE has been the topic of several other reports. HC Wainwright raised their price objective on uniQure from $50.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of uniQure in a research note on Friday, June 26th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price for the company in a report on Wednesday, June 17th. Finally, Wolfe Research upgraded shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a research note on Wednesday, July 29th. Fourteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.00.
Get Our Latest Analysis on QURE
uniQure Stock Down 0.8%
uniQure (NASDAQ:QURE – Get Free Report) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The business had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. During the same period in the prior year, the business posted ($0.69) EPS. Equities analysts expect that uniQure will post -3.82 earnings per share for the current fiscal year.
Insider Transactions at uniQure
In related news, insider Walid Abi-Saab sold 30,000 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total transaction of $1,392,600.00. Following the sale, the insider owned 148,235 shares in the company, valued at $6,881,068.70. The trade was a 16.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total value of $526,526.10. Following the completion of the transaction, the director directly owned 43,254 shares of the company’s stock, valued at approximately $1,949,025.24. The trade was a 21.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 385,584 shares of company stock worth $16,737,722. Insiders own 4.65% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Woodline Partners LP raised its holdings in uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after buying an additional 35,175 shares during the last quarter. Legal & General Group Plc bought a new stake in uniQure during the 2nd quarter worth approximately $497,000. Marshall Wace LLP increased its position in uniQure by 276.5% in the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock valued at $3,108,000 after acquiring an additional 163,749 shares during the period. California State Teachers Retirement System acquired a new position in uniQure in the 2nd quarter valued at approximately $540,000. Finally, Ameriprise Financial Inc. raised its stake in shares of uniQure by 38.6% during the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock valued at $10,622,000 after acquiring an additional 212,218 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.
uniQure Company Profile
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.
Read More
- Five stocks we like better than uniQure
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
